| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Cybin Inc. (NYSE:CYBN) (Cboe Canada:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, announced that, effective September 2, 2025, Doug Drysdale will step down as the Company's Chief Executive Officer.The Company's Co-Founder and President, Eric So, has been appointed as Interim Chief Executive Officer by the Board of Directors.
"Cybin was founded with a singular mission: to transform the treatment paradigm for mental health. With a solid foundation of clinical progress, regulatory recognition, and strong partnerships, we remain well-positioned to drive our programs forward," said Eric So, Interim Chief Executive Officer." "I am committed to ensuring continuity during this transition and to maintaining our focus on creating long-term value for both patients and shareholders."
Mr. So continued, "I want to thank Mr. Drysdale for his contributions. As Interim CEO, I look forward to executing on our strategy, advancing our clinical pipeline to successful approval of CYB003 and CYB004, and working closely with our partners as we move toward delivering innovative new therapies for patients in need."
Mr. So is a Co-founder and Executive Chairman of Cybin. He is a veteran owner, operator and investor in numerous companies over the last 20 years and has led corporate strategy, development, and finance at all stages of the business life cycle from start-up to growth stage and multinational.
The Board of Directorshas established a committee to conduct a search for a new Chief Executive Officer. The Committee and the Board aim to move swiftly to bring onboard a new leader who will lead the Company through commercialization and ensure that Cybin delivers on its commitment to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for patients.
Posted In: CYBN
